Seeking domestic partners
How the syndicate behind TCR2’s $125M series B could aid development in China
The syndicate behind TCR2 Therapeutics Inc.’s $125 million series B round includes a bevy of Chinese investors who could provide access to development and manufacturing partners in China.
6 Dimensions Capital and Curative Ventures led the untranched round. China-focused investors Hillhouse Capital, Syno Capital, Haitong International Securities